Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466302 | 0.80 | SLC6A2 (0.38) | DPP4ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL31588 | 0.79 | TDP1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL30147 | 0.79 | TDP1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL29178 | 0.79 | TDP1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL18832827 | 0.79 | TDP1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL12584889 | 0.79 | TDP1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL4249541 | 0.79 | TDP1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL28291453 | 0.78 | TAAR1 (0.37) | DPP4ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL30366682 | 0.77 | TDP1 (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL77070 | 0.77 | DPP4 (0.68) | DPP4ADRA2AADRA2CLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658825-B2 | Method for the preparation of aminophosphine ligands and their use in metal catalysts | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-02-25 | — | — | US | disclosed |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | PNISR, PRMT9, PRMT8 | DPP4 3995/4885ADRA2A 3778/4885ADRA2C 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.